Elevating AAV Care: Expert Strategies for Optimal Patient Outcomes

Discover the latest advances in ANCA-associated vasculitis (AAV). Tune in for valuable insights from our experts!

Live Meeting

1.00 available credits

Information

May 24, 2024

13:45 - 14:45 CEST

Stockholmsmässan
Mässvägen 1 Älvsjö, 125 80 Stockholm, Sweden, Room: A5

Details

Presenters

Comments

Overview
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a complex autoimmune disease. This condition can lead to life-threatening complications that primarily affect kidney function. Join renowned experts, Drs. Annette Bruchfeld, Stephen McAdoo, and Andreas Kronbichler, as they discuss insightful case presentations to unravel the latest advances in AAV induction and maintenance treatments and describe innovative approaches to managing patients with AAV.
Click here to register for the ERA Congress.
Program Schedule*
13:45 Welcome
13:49 Advancing AAV Care: A Patient-Centered Approach to Personalized Treatment and Improved Outcomes Presented by Dr. Andreas Kronbichler
13:59 2024 KDIGO Practice Guideline for the Management of AAV Presented by Dr. Annette Bruchfeld
14:02 Unveiling the Therapeutic Landscape of AAV: From Current Standards to Emerging Breakthroughs (Case Presentation 1) Presented by Dr. Stephen McAdoo
14:17 Unveiling the Therapeutic Landscape of AAV: From Current Standards to Emerging Breakthroughs (Case Presentation 2) Presented by Dr. Annette Bruchfeld
14:23 Panel Discussion and Take-Home Messages
14:35 Question & Answer Session
14:45 Adjourn
*Subject to Change
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Annette Bruchfeld, MD, PhD
Professor of Nephrology
Linköping University
Guest Professor
Karolinska Institutet
Unit of Renal Medicine
Stockholm, Sweden
Dr. Bruchfeld has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Alexion, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, and CSL Vifor
Faculty:
Stephen McAdoo, MD
Consultant Nephrologist
Imperial College Healthcare NHS Trust
London, United Kingdom
Dr. McAdoo has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: CSL Vifor, GSK
Research: AstraZeneca, Therini Bio
Andreas Kronbichler, MD
Assistant Professor
Medical University Innsbruck
Innsbruck, Austria
Dr. Kronbichler has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AstraZeneca, CSL Vifor, Delta4, GSK, Otsuka
Research: CSL Vifor
Reviewers/Content Planners/Authors:
- Ann Early has nothing to disclose.
- Cindy Davidson has nothing to disclose.
- Howard Green has nothing to disclose.
- Hany Ibrahim, MD, has nothing to disclose.
- Andrea Mathis has nothing to disclose.
- Kathleen Sheridan, PhD, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Identify the role of the alternative complement pathway in the pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)
- Evaluate the frequency of relapse and impact of medication-related toxicity associated with the use of traditional standard of care medications in the management of patients with AAV
- Develop patient-centered and evidence-based induction and maintenance treatment strategies to achieve sustained remission and mitigate treatment-associated toxicity in patients with AAV
Target Audience
This activity is designed to meet the educational needs of the practicing nephrologist and rheumatologist.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits^TM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.
Commercial Support
This activity is supported by an independent educational grant from CSL Vifor.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
ADA Statement
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+

Annette Bruchfeld, MD, PhD

Stephen McAdoo, MD

Andreas Kronbichler, MD

Details

Presenters

Comments

Overview
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a complex autoimmune disease. This condition can lead to life-threatening complications that primarily affect kidney function. Join renowned experts, Drs. Annette Bruchfeld, Stephen McAdoo, and Andreas Kronbichler, as they discuss insightful case presentations to unravel the latest advances in AAV induction and maintenance treatments and describe innovative approaches to managing patients with AAV.
Click here to register for the ERA Congress.
Program Schedule*
13:45 Welcome
13:49 Advancing AAV Care: A Patient-Centered Approach to Personalized Treatment and Improved Outcomes Presented by Dr. Andreas Kronbichler
13:59 2024 KDIGO Practice Guideline for the Management of AAV Presented by Dr. Annette Bruchfeld
14:02 Unveiling the Therapeutic Landscape of AAV: From Current Standards to Emerging Breakthroughs (Case Presentation 1) Presented by Dr. Stephen McAdoo
14:17 Unveiling the Therapeutic Landscape of AAV: From Current Standards to Emerging Breakthroughs (Case Presentation 2) Presented by Dr. Annette Bruchfeld
14:23 Panel Discussion and Take-Home Messages
14:35 Question & Answer Session
14:45 Adjourn
*Subject to Change
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Annette Bruchfeld, MD, PhD
Professor of Nephrology
Linköping University
Guest Professor
Karolinska Institutet
Unit of Renal Medicine
Stockholm, Sweden
Dr. Bruchfeld has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Alexion, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, and CSL Vifor
Faculty:
Stephen McAdoo, MD
Consultant Nephrologist
Imperial College Healthcare NHS Trust
London, United Kingdom
Dr. McAdoo has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: CSL Vifor, GSK
Research: AstraZeneca, Therini Bio
Andreas Kronbichler, MD
Assistant Professor
Medical University Innsbruck
Innsbruck, Austria
Dr. Kronbichler has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AstraZeneca, CSL Vifor, Delta4, GSK, Otsuka
Research: CSL Vifor
Reviewers/Content Planners/Authors:
- Ann Early has nothing to disclose.
- Cindy Davidson has nothing to disclose.
- Howard Green has nothing to disclose.
- Hany Ibrahim, MD, has nothing to disclose.
- Andrea Mathis has nothing to disclose.
- Kathleen Sheridan, PhD, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Identify the role of the alternative complement pathway in the pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)
- Evaluate the frequency of relapse and impact of medication-related toxicity associated with the use of traditional standard of care medications in the management of patients with AAV
- Develop patient-centered and evidence-based induction and maintenance treatment strategies to achieve sustained remission and mitigate treatment-associated toxicity in patients with AAV
Target Audience
This activity is designed to meet the educational needs of the practicing nephrologist and rheumatologist.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits^TM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.
Commercial Support
This activity is supported by an independent educational grant from CSL Vifor.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
ADA Statement
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+

Annette Bruchfeld, MD, PhD

Stephen McAdoo, MD

Andreas Kronbichler, MD

Pulmonary Hypertension Management: Practice Trends and Updates
Pulmonary Hypertension Management: Practice Trends and Updates
CME/CE Broadcast Replay
Pulmonary Hypertension Management: Practice Trends and Updates
1.00 credit
- Vallerie V. McLaughlin, MD
- Victor Moles, MD
- Ioana Preston, MD
1.00 credit
Risk Assessment in Pulmonary Hypertension: Practice Trends and Updates
Risk Assessment in Pulmonary Hypertension: Practice Trends and Updates
CME/CE Broadcast Replay
Risk Assessment in Pulmonary Hypertension: Practice Trends and Updates
1.00 credit
- Robert P. Frantz, MD, FACC
- Vallerie V. McLaughlin, MD
- Sonja Bartolomei, MD
1.00 credit
ns-MRAs: The Cardiovascular-Kidney-Metabolic Connection
ns-MRAs: The Cardiovascular-Kidney-Metabolic Connection
MinuteCE®
ns-MRAs: The Cardiovascular-Kidney-Metabolic Connection
1.25 program credits
- Csaba P. Kovesdy, MD
- Finnian R. Mc Causland, MD
1.25 program credits
Optimizing HF Outcomes Across the Spectrum: Emerging Evidence
Optimizing HF Outcomes Across the Spectrum: Emerging Evidence
MinuteCE®
Optimizing HF Outcomes Across the Spectrum: Emerging Evidence
1.25 program credits
- Akshay S. Desai, MD
- John McMurray, MD
1.25 program credits

Recommended

Title

Share on ReachMD